Jonathan Kay to Drug Substitution
This is a "connection" page, showing publications Jonathan Kay has written about Drug Substitution.
Connection Strength
0.186
-
Scheinberg MA, Kay J. The advent of biosimilar therapies in rheumatology--"O brave new world". Nat Rev Rheumatol. 2012 06 05; 8(7):430-6.
Score: 0.099
-
Ogdie A, Reddy SM, Gillespie SH, Husni ME, Scher JU, Salomon-Escoto K, Kay J, Luedders BA, Curtis JR, Shields AJS, Chakravarty SD, Gong C, Walsh JA. Guselkumab versus golimumab in patients with active psoriatic arthritis and inadequate response to an initial tumor necrosis factor inhibitor: study protocol for EVOLUTION, a pragmatic, phase 3b, open-label, randomized, controlled effectiveness trial. Trials. 2025 Mar 19; 26(1):96.
Score: 0.060
-
Smolen JS, Kay J, Matteson EL, Landew? R, Hsia EC, Xu S, Zhou Y, Doyle MK. Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study. Ann Rheum Dis. 2014 Oct; 73(10):1811-8.
Score: 0.027